A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver

2024-515417-17-00 Protocol 14040047 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 1 Oct 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 14040047

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 1

No targeted indication. Male and female subjects with obesity.

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Metabolism [G03]
Trial duration
1 Oct 2024 → ongoing
Decision date (initial)
2024-10-28
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515417-17-00
EudraCT number
2021-000363-76

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No targeted indication. Male and female subjects with obesity.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 30 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Academisch Medisch Centrum
#NDL1 Pharmacy, Meibergdreef 9, 1105 AZ, Amsterdam

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-10-01 2024-10-01

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-02 Netherlands Acceptable
2024-10-28
2024-10-28
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-18 Netherlands Acceptable
2025-11-25
2025-11-25